CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex
Authors
Keywords
Tuberous sclerosis complex, Angiomyolipomas, mTOR inhibitor, Influence factors
Journal
INTERNATIONAL UROLOGY AND NEPHROLOGY
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-02-11
DOI
10.1007/s11255-019-02093-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Assessment of Tuberous Sclerosis Complex Associated With Renal Lesions by Targeted Next-generation Sequencing in Mainland China
- (2017) Yi Cai et al. UROLOGY
- Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis
- (2016) Klemens Budde et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions
- (2016) Paolo Curatolo et al. DRUGS
- Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex
- (2015) Jeffrey P. MacKeigan et al. NEURO-ONCOLOGY
- Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
- (2013) John J Bissler et al. LANCET
- Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
- (2013) Darcy A. Krueger et al. PEDIATRIC NEUROLOGY
- Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
- (2013) Hope Northrup et al. PEDIATRIC NEUROLOGY
- Similar Trends in Serum VEGF-D Levels and Kidney Angiomyolipoma Responses with Longer Duration Sirolimus Treatment in Adults with Tuberous Sclerosis
- (2013) Izabela A. Malinowska et al. PLoS One
- Topical Rapamycin Therapy to Alleviate the Cutaneous Manifestations of Tuberous Sclerosis Complex
- (2013) Mary Kay Koenig et al. Drugs in research & development
- Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
- (2012) Cristina Cabrera-López et al. Orphanet Journal of Rare Diseases
- Tuberous Sclerosis Complex–Associated Angiomyolipomas: Focus on mTOR Inhibition
- (2011) Klemens Budde et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial
- (2011) D. M. Davies et al. CLINICAL CANCER RESEARCH
- Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
- (2011) Francis X. McCormack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease
- (2011) Sandra L. Dabora et al. PLoS One
- Tuberous Sclerosis Complex Renal Disease
- (2010) Bradley P. Dixon et al. NEPHRON EXPERIMENTAL NEPHROLOGY
- Renal Angiomyolipoma
- (2009) Hakan Aydin et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
- (2008) John J. Bissler et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started